ECP 2019 Final Programme

Tuesday, 10 Sept 183 ECP 2019 · Nice Breakfast and Luncheon Industry Symposia LS-07 Industry Symposium 13:00–14:30 Thalie Shifting biomarker paradigms in advanced/metastatic breast cancer – looking towards PIK3CA and beyond (Novartis) Chair: Federico Rojo, Spain 001 13:00–13:05 Welcome and introduction Federico Rojo, Spain 002 13:05–13:25 Emerging biomarkers in advanced/ metastatic breast cancer from a clinician’s perspective Fabrice André, France 003 13:25–13:30 Q&A Fabrice André, France 004 13:30–13:45 Optimising laboratory workflows to include PIK3CA mutation testing in breast-cancer diagnostics Federico Rojo, Spain 005 13:45–13:50 Q&A Federico Rojo, Spain 006 13:50–14:05 Quality assurance issues for PIK3CA testing in practice Michael Hummel, Germany 007 14:05–14:10 Q&A Michael Hummel, Germany 008 14:10–14:25 Consensus or conflict: expert views on biomarker testing in advanced/metastatic breast cancer All faculty 009 14:25–14:30 Meeting closure Federico Rojo, Spain e Tuesday, 10 September 2019 LS-14 Industry Symposium 13:00–14:30 Apollon Changing paradigms: the utility and efficiency of Comprehensive Tumour Profiling in the pathology lab (Illumina) Chair: Nicola Normanno, Italy 001 Transforming oncology with Comprehensive Genomic Profiling David Eberhard, USA 002 Real world experience with – TruSight TM Oncology 500 a pan–cancer sequencing essay Andrew Beggs, United Kingdom 003 SMP2: bringing the value of Comprehensive Genomic Profiling into a national health system Rowena Sharpe, United Kingdom 004 Q&A Nicola Normanno, Italy LS-12 Industry Symposium 13:00–14:30 Hermès High expectations, limited samples: ensuring tissue is no longer an issue for patients with lung cancer (AstraZeneca) Chair: Aleš Ryška, Czech Republic 001 13:00–13:05 Welcome Aleš Ryška, Czech Republic 002 13:05–13:30 Best practice guidance for ensuring samples consistently meet the diagnostic obligations for targeted therapy Luka Brcic, Croatia 003 13:30–13:55 Panel testing or single gene testing: is there an optimal approach? Reinhard Büttner, Germany 004 13:55–14:05 Q&A Aleš Ryška, Czech Republic Monday, 9 Sept